ERBB2 and breast carcinoma: This is in line with the meta-analysis from five randomized trials,10 where a differential benefit among patients with HER2 normal breast cancer was indicated, and the benefit of anthracycline for the triple negative subgroup seemed more pronounced compared to the results for patients with luminal subtypes.